๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

89Strontium therapy of bone metastases of carcinoma of the prostatic gland

โœ Scribed by Hans-Jacob Correns; Moritz Mebel; Klaus Buchali; Dietmar Schnorr; Christian Seidel; Egon Mitterlechner

Publisher
Springer
Year
1979
Tongue
English
Weight
179 KB
Volume
4
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

โœฆ Synopsis

Following a firm diagnostic and therapeutic schedule for patients with prostatic carcinoma. 89Strontium therapy was introduced for multiple metastases. Positive skeletal scintigraphy with 99mTc-EHDP induced check for affinity to Sr using 85Sr scintigraphy. Of 80 patients, multiple metastases were found in 26. Therapy with 1 mCi of 89Sr-chloride was started in 20 cases. In 8 patients, relief from severe pain appeared shortly afterward, and a further 8 it was possible to prevent the development of pain. Moderate success in 3 cases and a failure to provide relief in 1 were observed.

๐Ÿ“œ SIMILAR VOLUMES

Results of a double blind study of 89-st
Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma
โœ Klaus Buchali; Hans-Jacob Correns; Michael Schuerer; Dietmar Schnorr; Hildegard ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer ๐ŸŒ English โš– 249 KB

Forty-nine patients were treated with either 3 x 75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covar

Sr-89 therapy: Strontium kinetics in dis
Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate
โœ G. M. Blake; M. A. Zivanovic; A. J. McEwan; D. M. Ackery ๐Ÿ“‚ Article ๐Ÿ“… 1986 ๐Ÿ› Springer ๐ŸŒ English โš– 824 KB

Strontium kinetics were investigated in a group of 14 patients receiving 89Sr palliation for metastatic bone disease secondary to prostatic carcinoma. Using 85Sr as a tracer, total body strontium retention R(t) was monitored for a 3 month period following 89Sr administration, and at 90 days was foun

A Phase I/II study of strontium-89 combi
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases
โœ Lance C. Pagliaro; Ebrahim S. Delpassand; Dallas Williams; Randall E. Millikan; ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 87 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND The objectives of the current study were to determine the maximum tolerated dose and to evaluate the efficacy of gemcitabine given in combination with strontiumโ€89 to patients with androgen independent prostate carcinoma. ## METHODS Patients with androgenโ€independent pr